Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Second medical opinions: the views of oncology patients and their physicians

Philip J, Gold M, Schwarz M, Komesaroff P

(2010), Support Care Cancer, 18(9), 1199-205

The relationship between hormone therapy use at the time of diagnosis of breast cancer and tumor characteristics

Panjari M, Bell R, Lijovic M, La China M, Schwarz M, Fradkin P, Bradbury J, Farrugia H, Davis SR

(2010), Horm Canc, 1(2), 93-9

Psychological well-being in a cohort of women with invasive breast cancer nearly 2 years after diagnosis

Bell RJ, Lijovic M, La China M, Schwarz M, Fradkin P, Bradbury J, Davis SR

(2010), Support Care Cancer, 18(8), 921-9

Use of complementary and alternative therapy by women in the first 2 years after diagnosis and treatment of invasive breast cancer

Davis SR, Lijovic M, Fradkin P, Bradbury J, La China M, Schwarz M, Bell RJ

(2010), Menopause, 17(5), 1004-9

O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib

Watson AJ, Middleton MR, McGown G, Thorncroft M, Ranson M, Hersey P, McArthur G, Davis ID, Thomson D, Beith J, Haydon A, Kefford R, Lorigan P, Mortimer P, Sabharwal A, Hayward O, Margison GP

(2009), Br J Cancer, 100(8), 1250-6

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93

Thürlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A

(2009), Breast Cancer Res Treat, 113(1), 137-44

Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group

Gianni L, Gelber S, Ravaioli A, Price KN, Panzini I, Fantini M, Castiglione-Gertsch M, Pagani O, Simoncini E, Gelber RD, Coates AS, Goldhirsch A

(2009), Eur J Cancer , 45(4), 561–71

Patients' views on decision making in advanced cancer

Philip J, Gold M, Schwarz M, Komesaroff P

(2009), Palliat Support Care, 7(2), 181-5

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93

Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E,Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group

(2009), Breast Cancer Res Treat, 116(3), 491-500

What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century?

Olver IN, Haines IE

(2009), Med J Aust, 190(2), 74-7

The relationship between knowledge of family history and cancer characteristics at diagnosis in women newly-diagnosed with invasive breast cancer

Lijovic M, Davis SR, Fradkin P, Bradbury J, La China M, Schwarz M, Wolfe R, Farrugia H, Bell RJ

(2009), Fam Cancer, 8(4), 299-305

An Australian clinical perspective: management of hormone refractory (androgen-independent) prostate cancer

Hovey E, Marx G, Kneebone A, Patel M, Shapiro J

(2009), Asia-Pacific J Oncol Hematol, 1(1), 82-3

Are guidelines on use of colony-stimulating factors in solid cancers flawed?

Haines IE, Olver I

(2009), Intern Med J, 39(4), 259-62

A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia

Haines I, Elliott P, Stanley R

(2009), Intern Med J, 39(4), 269-71

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group

(2009), Clin Trials, 6(3), 272-87

Lack of knowledge of hormone receptor status and use of endocrine therapy in invasive breast cancer

Bell RJ, Lijovic M, Fradkin P, Bradbury J, La China M, Schwarz M, Wolfe R, Farrugia H, Davis SR

(2009), J Womens Health, 18(12), 1975-80

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer

Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, et al; International Breast Cancer Study Group

(2008), J Natl Cancer Inst, 100(3), 207-12

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study G

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS

(2008), J Clin Oncol, 26(9), 1404-10

Re: Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial

Sari E, Bulut N, Altundag K

(2008), J Natl Cancer Inst, 100(9), 683

p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer

Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G; International Breast Cancer Study Group

(2008), Ann Oncol, 19(4), 660-8

6 7 8 9 10